Yazici et al. RCT of IA Lorecivivint for moderate/severe knee OA. CLK/DYRK inhibitor. No effect seen. @RheumNow #ACR22 Abstr#1899 https://t.co/XGQrMmNnSR https://t.co/rSJrT6Hms6
Links:
A Phase 3, 28-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled T…
https://acrabstracts.org/abstract/a-phase-3-28-week-multicenter-randomized-doub…
14-11-2022